• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Jazz Pharmaceuticals plc

    4/1/26 4:03:51 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JAZZ alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001193210
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Jazz Pharmaceuticals Plc
    SEC File Number
    001-33500
    Address of Issuer
    5th Floor Waterloo Exchange
    Waterloo Road
    Dublin
    IRELAND
    D04 E5W7
    Phone
    353-1-634-7800
    Name of Person for Whose Account the Securities are To Be Sold
    Bruce C Cozadd
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Merrill Lynch
    3075A Hansen Way 1st Floor
    Palo Alto � CA � 94304
    60001143010.36156035004/01/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common01/03/2022Stock OptionJazz Pharmaceuticals PLCCheckbox not checked134401/03/2022Cash
    Common01/03/2022Stock OptionJazz Pharmaceuticals PLCCheckbox not checked390901/03/2022Cash
    Common02/01/2022Stock OptionJazz Pharmaceuticals PLCCheckbox not checked74702/01/2022Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Bruce Cozadd
    5th Floor Waterloo Exchange
    Waterloo Road
    Dublin � L2 � D04-E5W7
    Common03/03/202660001118613.32

    144: Remarks and Signature

    Remarks
    Date of Notice
    04/01/2026
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    11/26/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Bruce C Cozadd

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $JAZZ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JAZZ

    DatePrice TargetRatingAnalyst
    5/22/2026$229.00Mkt Perform
    Bernstein
    5/19/2026$307.00Neutral → Buy
    UBS
    4/10/2026$227.00Outperform
    Raymond James
    2/27/2026$224.00Overweight
    Barclays
    11/24/2025$188.00Buy → Neutral
    UBS
    7/15/2025$152.00Buy
    Deutsche Bank
    3/7/2025$145.00 → $179.00Neutral → Buy
    UBS
    2/26/2025Overweight → Neutral
    Cantor Fitzgerald
    More analyst ratings

    $JAZZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bernstein initiated coverage on Jazz Pharma with a new price target

    Bernstein initiated coverage of Jazz Pharma with a rating of Mkt Perform and set a new price target of $229.00

    5/22/26 8:41:12 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharma upgraded by UBS with a new price target

    UBS upgraded Jazz Pharma from Neutral to Buy and set a new price target of $307.00

    5/19/26 8:27:50 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on Jazz Pharma with a new price target

    Raymond James resumed coverage of Jazz Pharma with a rating of Outperform and set a new price target of $227.00

    4/10/26 12:21:53 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    SEC Filings

    View All

    SEC Form 144 filed by Jazz Pharmaceuticals plc

    144 - Jazz Pharmaceuticals plc (0001232524) (Subject)

    6/1/26 4:13:28 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Jazz Pharmaceuticals plc

    PRE 14A - Jazz Pharmaceuticals plc (0001232524) (Filer)

    5/29/26 4:11:02 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals plc filed SEC Form 8-K: Leadership Update

    8-K - Jazz Pharmaceuticals plc (0001232524) (Filer)

    5/29/26 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cozadd Bruce C sold $1,410,720 worth of Ordinary Shares (6,000 units at $235.12) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 372,682 units (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    6/3/26 5:09:45 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Chief Legal Officer Patil Neena M sold $282,468 worth of Ordinary Shares (1,192 units at $236.97) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 52,626 units (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    6/1/26 4:09:43 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Commercial Officer Pearce Samantha exercised 6,907 units of Ordinary Shares at a strike of $109.45 and sold $1,625,977 worth of Ordinary Shares (6,907 units at $235.41) (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    6/1/26 4:06:22 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

    Expanded safety, subgroup, progression-free survival sensitivity and subsequent therapy analyses further characterize the consistency and durability of outcomes observed with zanidatamab-containing combinations in the first-line settingAdditional subgroup analyses to be presented at the 2026 ASCO Annual Meeting show improved clinical outcomes with zanidatamab-containing combinations regardless of PD-L1 expression, including in PD-L1-negative patientsFor U.S. media and investors only  DUBLIN, May 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the New England Journal of Medicine has published the Phase 3 HERIZON-GEA-01 trial results, further characterizing

    5/27/26 5:00:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

    DUBLIN, May 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that company management will participate in fireside chats at the following investor conferences:2026 RBC Global Healthcare Conference on Tuesday, May 19, 2026 at 8:00 a.m. ETTD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 27, 2026 at 2:00 p.m. ET2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 10:30 a.m. ETAudio webcasts of the fireside chats will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on the

    5/12/26 4:15:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results

    – Strong commercial execution across franchises with total revenues of $1.1 billion (+19% YoY) –– Zanidatamab HER2+ 1L GEA sBLA granted Priority Review; PDUFA date of August 25, 2026 –– Xywav® revenues grew 18% YoY with 425 net patient adds –– Epidiolex® revenues grew 15% YoY–– Company reaffirms 2026 revenue and expense guidance –DUBLIN, May 5, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the first quarter of 2026 (1Q26)."Our first-quarter results reflect disciplined execution across the business, delivering 19% year-over-year growth alongside key pipeline advancements and positioning the company for an outstanding 2026," said Renee Gala,

    5/5/26 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mulligan Seamus bought $9,993,082 worth of Ordinary Shares (101,621 units at $98.34) (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    5/13/25 6:51:34 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson Philip L was granted 15,932 units of Ordinary Shares and bought $1,435,800 worth of Ordinary Shares (12,000 units at $119.65) (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    3/5/24 7:28:40 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 12, 2021 - FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment

    For Immediate Release: August 12, 2021 The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults. IH is an uncommon chronic sleep disorder that causes people to be excessively sleepy during the day even after a good night's sleep. Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is already approved for the treatment of catapl

    8/12/21 4:25:43 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Leadership Updates

    Live Leadership Updates

    View All

    Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer

    Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions DUBLIN, Jan. 8, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026. Mr. Riga joined Jazz in April 2025 through the acquisition of Chimerix Inc., where he served as chief operating and commercial officer. In that role, he directed corporate strategy including the successful sale of Chimerix to Jazz. In addition to leading the transaction process and alliance management at Chimerix, he helped navigate a complex regulatory env

    1/8/26 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors

    Dr. Love, a biopharmaceutical industry veteran, brings extensive executive leadership and board experience with proven success in creating shareholder value DUBLIN, Oct. 28, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that Ted W. Love, M.D., has been appointed to the Company's Board of Directors, effective December 1, 2025. Dr. Love brings more than 30 years of expertise in drug development and global commercialization to the Company's Board.  "We are thrilled to welcome Ted to the Board," said Renee Gala, president and CEO, Jazz Pharmaceuticals. "His proven success in the biopharmaceutical industry and track record driving scientific innovation, commercial su

    10/28/25 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer

    – Selection Follows Robust Succession Process Led by the Board – – Bruce Cozadd to Retire as CEO and Remain Chairperson of the Board of Directors – DUBLIN, July 10, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Jazz Board of Directors has unanimously selected Renee Gala, Jazz's President and Chief Operating Officer, as the President and Chief Executive Officer, effective August 11, 2025, when she will also join the Board. She will succeed co-founder, Chairperson and CEO Bruce Cozadd, who informed the Board in December 2024 of his intent to retire as CEO upon the identification of the Company's next leader. This appointment reflects a key milestone in t

    7/10/25 7:30:00 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Financials

    Live finance-specific insights

    View All

    Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results

    – Strong commercial execution across franchises with total revenues of $1.1 billion (+19% YoY) –– Zanidatamab HER2+ 1L GEA sBLA granted Priority Review; PDUFA date of August 25, 2026 –– Xywav® revenues grew 18% YoY with 425 net patient adds –– Epidiolex® revenues grew 15% YoY–– Company reaffirms 2026 revenue and expense guidance –DUBLIN, May 5, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the first quarter of 2026 (1Q26)."Our first-quarter results reflect disciplined execution across the business, delivering 19% year-over-year growth alongside key pipeline advancements and positioning the company for an outstanding 2026," said Renee Gala,

    5/5/26 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026

    DUBLIN, April 21, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced it will report its 2026 first quarter financial results on Tuesday, May 5, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to discuss the results and provide a business and financial update.Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.A replay of the webcast will be available via the Investors section of

    4/21/26 4:15:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance

    – Record total revenues of $4.3 billion in 2025 (+5% YoY) and $1.2 billion (+10% YoY) in 4Q25 –– Expect to complete sBLA submission in 1Q26 under RTOR for zanidatamab in HER2+ 1L GEA –– Xywav® achieved $1.7 billion in revenue and 12% YoY growth in 2025 –– Epidiolex® achieved $1.1 billion in revenue and 9% YoY growth in 2025 –– Strong Modeyso™ launch with $37 million in revenue in first full quarter on market –– Expect 2026 total revenues of $4.25 to $4.50 billion –DUBLIN, Feb. 24, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the full year and fourth quarter of 2025 and provided financial guidance for 2026."2025 was an exceptional year for

    2/24/26 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

    SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

    2/13/24 5:07:58 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

    SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

    9/11/23 1:33:44 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

    SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

    2/9/23 11:25:15 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care